(Q35537181)

English

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment

scientific article published on 29 July 2005

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

1 reference

Europe PubMed Central

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Mycobacterium tuberculosis

0 references

0 references

0 references

author name string

British Thoracic Society Standards of Care Committee

1

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

language of work or name

0 references

publication date

29 July 2005

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

60

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

800-805

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1747200

27 July 2018

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1747200

27 July 2018

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1747200

27 July 2018

Cytokine pathways and joint inflammation in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1747200

27 July 2018

Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1747200

27 July 2018

New drugs for the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1747200

27 July 2018

Tuberculosis in England and Wales in 1993: results of a national survey. Public Health Laboratory Service/British Thoracic Society/Department of Health Collaborative Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1747200

27 July 2018

High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1747200

26 September 2018

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1747200

26 September 2018

Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1747200

26 September 2018

Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1747200

26 September 2018

The treatment of tuberculosis in HIV-infected persons.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1747200

26 September 2018

Disturbed hepatic function during isoniazid chemoprophylaxis. Monitoring the hepatic function of 427 hospital employees receiving isoniazid chemoprophylaxis for tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16055611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference

1 reference

https://pubmed.ncbi.nlm.nih.gov/16055611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic

1 reference

https://pubmed.ncbi.nlm.nih.gov/16055611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/THX.2005.046797

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35537181&oldid=2139333622"